{
  "ticker": "GILD",
  "timestamp": "2025-07-21T04:32:05.610373",
  "companies": [
    "Gilead Sciences, Inc.",
    "GILD",
    "Gilead",
    "Gilead Sciences",
    "Gilead Sciences’",
    "Leerink Partnrs",
    "Zacks.com",
    "Zacks",
    "Pomerantz LLP",
    "Pomerantz Law Firm",
    "AI"
  ],
  "people": [
    "Tamar Braxton",
    "Andrew Dickinson"
  ],
  "sentiment": {
    "overall": "neutral",
    "positive_count": 0,
    "negative_count": 0,
    "neutral_count": 0
  },
  "industry": "healthcare",
  "key_points": [
    {
      "text": "Leerink Partnrs raised its Q3 2025 EPS estimate for Gilead to $2.37 from $2.26, reflecting improved near-term earnings expectations.\nLeerink Partnrs Raises Q3 2025 EPS Estimate for Gilead Sciences\nNeutral Sentiment:\nA new HIV 7MM drug forecast report projects the market to reach $32.1 billion by 203",
      "importance_score": 89,
      "sentiment": "neutral"
    },
    {
      "text": "Leerink Partnrs cut its Q2 2025 EPS forecast for Gilead to $1.91 from $2.25, signaling softer near-term earnings expectations.\nGilead Sciences Q2 EPS Estimate Lowered by Leerink Partnrs\nNegative Sentiment:\nPomerantz LLP launched an investor investigation into Gilead over undisclosed claims, introduc",
      "importance_score": 81,
      "sentiment": "negative"
    },
    {
      "text": "Gilead’s CFO, Andrew Dickinson, sold 2,500 shares for about $277,575, reducing his stake by 1.5%, which may raise governance or insider-confidence concerns.\nGilead Sciences, Inc. (NASDAQ:GILD) CFO Sells $277,575.00 in Stock\nPosted 1+ days ago\nAI Generated. May Contain Errors.",
      "importance_score": 75,
      "sentiment": "neutral"
    },
    {
      "text": "Gilead Sciences, Inc. (GILD) is Attracting Investor Attention\nNeutral Sentiment:\nAnother Zacks article on medical stocks mentioned Gilead in a broader earnings-beat screen, but without company-specific forecasts or drivers.",
      "importance_score": 33,
      "sentiment": "neutral"
    },
    {
      "text": "Tamar Braxton Is Raising Awareness About The Power Of PrEP Under Her New Partnership With Gilead Sciences\nPositive Sentiment:\nAn updated study on sacituzumab govitecan highlighted new data and market implications for Gilead’s cancer‐targeting antibody-drug conjugate, underlining potential revenue up",
      "importance_score": 30,
      "sentiment": "positive"
    }
  ],
  "money_amounts": [
    "2.37",
    "2.26",
    "$32.1 billion",
    "1.91",
    "2.25",
    "about $277,575",
    "277,575.00"
  ],
  "important_dates": [
    "Q3 2025",
    "2033",
    "Q2 2025",
    "Q2",
    "1+ days ago"
  ],
  "financial_keywords": [],
  "key_relationships": [
    {
      "subject": "Braxton",
      "verb": "Raising",
      "object": "Awareness",
      "importance": 9
    },
    {
      "subject": "study",
      "verb": "highlighted",
      "object": "data",
      "importance": 9
    },
    {
      "subject": "Partnrs",
      "verb": "raised",
      "object": "estimate",
      "importance": 24
    },
    {
      "subject": "Partnrs",
      "verb": "Raises",
      "object": "Estimate",
      "importance": 24
    },
    {
      "subject": "market",
      "verb": "reach",
      "object": "billion",
      "importance": 24
    }
  ],
  "business_context": [],
  "compact_analysis": "{\"ticker\": \"GILD\", \"companies\": [\"Gilead Sciences, Inc.\", \"GILD\", \"Gilead\", \"Gilead Sciences\", \"Gilead Sciences’\", \"Leerink Partnrs\", \"Zacks.com\", \"Zacks\", \"Pomerantz LLP\", \"Pomerantz Law Firm\", \"AI\"], \"people\": [\"Tamar Braxton\", \"Andrew Dickinson\"], \"sentiment\": {\"overall\": \"neutral\", \"positive_count\": 0, \"negative_count\": 0, \"neutral_count\": 0}, \"industry\": \"healthcare\", \"key_points\": [{\"text\": \"Leerink Partnrs raised its Q3 2025 EPS estimate for Gilead to $2.37 from $2.26, reflecting improved near-term earnings expectations.\\nLeerink Partnrs Raises Q3 2025 EPS Estimate for Gilead Sciences\\nNeutral Sentiment:\\nA new HIV 7MM drug forecast report projects the market to reach $32.1 billion by 203\", \"importance_score\": 89, \"sentiment\": \"neutral\"}, {\"text\": \"Leerink Partnrs cut its Q2 2025 EPS forecast for Gilead to $1.91 from $2.25, signaling softer near-term earnings expectations.\\nGilead Sciences Q2 EPS Estimate Lowered by Leerink Partnrs\\nNegative Sentiment:\\nPomerantz LLP launched an investor investigation into Gilead over undisclosed claims, introduc\", \"importance_score\": 81, \"sentiment\": \"negative\"}, {\"text\": \"Gilead’s CFO, Andrew Dickinson, sold 2,500 shares for about $277,575, reducing his stake by 1.5%, which may raise governance or insider-confidence concerns.\\nGilead Sciences, Inc. (NASDAQ:GILD) CFO Sells $277,575.00 in Stock\\nPosted 1+ days ago\\nAI Generated. May Contain Errors.\", \"importance_score\": 75, \"sentiment\": \"neutral\"}, {\"text\": \"Gilead Sciences, Inc. (GILD) is Attracting Investor Attention\\nNeutral Sentiment:\\nAnother Zacks article on medical stocks mentioned Gilead in a broader earnings-beat screen, but without company-specific forecasts or drivers.\", \"importance_score\": 33, \"sentiment\": \"neutral\"}, {\"text\": \"Tamar Braxton Is Raising Awareness About The Power Of PrEP Under Her New Partnership With Gilead Sciences\\nPositive Sentiment:\\nAn updated study on sacituzumab govitecan highlighted new data and market implications for Gilead’s cancer‐targeting antibody-drug conjugate, underlining potential revenue up\", \"importance_score\": 30, \"sentiment\": \"positive\"}], \"money_amounts\": [\"2.37\", \"2.26\", \"$32.1 billion\", \"1.91\", \"2.25\", \"about $277,575\", \"277,575.00\"], \"important_dates\": [\"Q3 2025\", \"2033\", \"Q2 2025\", \"Q2\", \"1+ days ago\"], \"financial_keywords\": [], \"key_relationships\": [{\"subject\": \"Braxton\", \"verb\": \"Raising\", \"object\": \"Awareness\", \"importance\": 9}, {\"subject\": \"study\", \"verb\": \"highlighted\", \"object\": \"data\", \"importance\": 9}, {\"subject\": \"Partnrs\", \"verb\": \"raised\", \"object\": \"estimate\", \"importance\": 24}, {\"subject\": \"Partnrs\", \"verb\": \"Raises\", \"object\": \"Estimate\", \"importance\": 24}, {\"subject\": \"market\", \"verb\": \"reach\", \"object\": \"billion\", \"importance\": 24}], \"business_context\": []}"
}